In June 2024, the landscape of paediatric oncology in the UK underwent a significant transformation with the introduction of the first-ever targeted therapy for children with brain tumours by NHS England. This therapy, which combines the drugs dabrafenib and trametinib, specifically targets gliomas with a BRAF gene mutation. This breakthrough offers a new lease on life for children who previously had limited treatment options, marking a significant advancement in the fight against paediatric brain cancer. It represents a shift towards more personalised medicine, which tailors’ treatments to the specific genetic makeup of each patient’s tumour, improving outcomes and reducing harmful side effects.
Understanding Gliomas and the BRAF Gene Mutation
Gliomas are the most common type of brain tumour in children, accounting for nearly half of all paediatric brain tumours. These tumours arise from glial cells, which are the supportive cells of the brain. Gliomas can be classified into low-grade, which grow slowly and may not cause immediate symptoms, and high-grade, which are aggressive and can rapidly cause serious neurological symptoms.
The BRAF gene mutation is a genetic alteration that drives the growth of a subset of these gliomas. This mutation causes the BRAF protein to be constantly active, sending signals to the tumour cells to keep dividing uncontrollably. Traditional treatments, such as surgery, chemotherapy, and radiation, are often not sufficient to control these tumours, especially when the BRAF mutation is present. The new therapy introduced by the NHS targets this mutation directly, offering a more effective and less harmful approach.
Clinical Trials: The Road to Approval
The journey to the approval of this targeted therapy was paved by years of rigorous clinical research. The pivotal TADPOLE-G study played a crucial role in demonstrating the effectiveness of dabrafenib and trametinib in treating BRAF-mutated gliomas in children. This study compared the outcomes of children treated with the drug combination to those receiving standard chemotherapy, and the results were groundbreaking.
In the TADPOLE-G trial, children treated with the combination of dabrafenib and trametinib showed a significantly higher overall response rate compared to those treated with chemotherapy. The trial reported that tumours shrank more frequently and remained under control for longer periods, with a median progression-free survival that far exceeded that of standard treatments. In addition, the side effects were notably milder, with children experiencing fewer of the debilitating symptoms often associated with chemotherapy, such as nausea, fatigue, and hair loss.
The ability to take these medications orally at home also represents a major improvement in the quality of life for these young patients, reducing the need for hospital visits and allowing them to maintain a sense of normalcy during their treatment.
The positive results from the TADPOLE-G study led to the fast-tracking of this therapy’s approval by NHS England, which recognised the urgent need for more effective treatments for paediatric brain tumours. This approval is a milestone in paediatric oncology, offering new hope to families affected by this devastating disease.
The Impact on Paediatric Brain Cancer Treatment
The introduction of dabrafenib and trametinib marks a significant shift in how paediatric brain tumours are treated in the UK. For children with BRAF-mutated gliomas, this therapy offers a targeted approach that is not only more effective but also comes with fewer side effects compared to traditional chemotherapy. By focusing on the genetic drivers of the tumour, this treatment can slow the progression of the disease and improve the overall prognosis for these children.
This therapy is part of a broader movement towards personalised medicine, where treatments are tailored to the individual characteristics of a patient’s tumour. As researchers continue to uncover the genetic underpinnings of various cancers, the potential for developing additional targeted therapies grows, offering hope for more children diagnosed with different types of brain tumours.
The success of dabrafenib and trametinib also underscores the importance of ongoing research into the genetic and molecular mechanisms that drive paediatric brain tumours. Understanding these mechanisms is key to developing new treatments that can address the specific challenges posed by different tumour subtypes. This approach not only improves the effectiveness of treatments but also reduces the risk of long-term side effects, which is particularly important for young patients who may live for many decades after their treatment.
At Joss Searchlight, we have long recognised the critical need for more personalised and effective treatments for children with brain cancer. The introduction of targeted therapies like dabrafenib and trametinib represents the kind of innovative approach that we are committed to supporting. Our mission is to ensure that every child diagnosed with a brain tumour has access to the most advanced and least harmful treatments available.
Over the years, we have funded numerous research projects aimed at understanding the genetic drivers of paediatric brain tumours. The success of these efforts is evident in the groundbreaking advancements we see today. However, the work is far from over. Continued research is essential to expand the availability of targeted therapies and to refine existing treatments to make them even more effective and accessible.
Joss Searchlight is also dedicated to raising awareness about the importance of research into paediatric brain tumours. We advocate for increased funding from both public and private sources, and we work to ensure that families have access to the information and support they need to navigate the challenges of a brain tumour diagnosis.
Your donations to Joss Searchlight directly contribute to funding the research that makes these life-saving treatments a reality. By supporting our work, you are helping to ensure that children with brain cancer have the best possible chance of a cure. Please consider making a donation today. Your generosity will help us continue to fund vital research, support families affected by brain cancer, and advocate for policies that ensure all children have access to the best possible care.
Help us find a cure for rare brain tumours and give support today
